Built for Life Science Startups. Backed by Experts.
Science Inc. | Life Sciences is a 14-week accelerator helping founders de-risk, connect, and grow.
Applications for Fall 2026 open May 15.
About the Science Inc.™ | Life Sciences Accelerator
Science Inc. | Life Sciences is designed for early-stage startups advancing complex life science technologies. Each cohort provides deep commercialization support, expert mentorship, and high-impact connections.
Our Fall 2026 cohort is dedicated to Life Sciences startups developing:
- Novel therapeutics
- Platform biotechnologies
- Drug delivery systems
- Medical devices with an advanced materials component
- Enabling tools in cell and gene therapy, synthetic biology, or biomanufacturing
What You’ll Gain
Sector-Specific Curriculum
The 14-week hybrid program focuses on critical areas for founders in biotech and therapeutic innovation:
- Key milestones and value inflection points
- Clinical and regulatory strategy
- Data room elements
- Investor outreach and engagement
Expert Mentorship & Strategic Support
You’ll be connected to seasoned industry leaders, investors, and technical advisors who understand the regulatory, scientific, and business dynamics of life science innovation.
Resources & Community Access
Founders can tap into The Innovation Space’s community of experts, as well as exclusive perks like PitchBook access, onsite coworking, founder events, and targeted partner introductions.
Visibility & Investor Connections
Demo Day and curated pitch opportunities help you tell your story, gain exposure, and build relationships with investors and stakeholders focused on early-stage life sciences.
Program Snapshot
- Timeline: August–December 2026
- Format: Hybrid (virtual delivery + 2 Required In-Person Events)
- Location: Virtual + Wilmington, DE
- Application Deadline: July 8, 2026
Key In-Person Events
- October 9: Live Pitch Workshop
- December 9–10: Final Pitch Event & Science Inc. Days Celebration
Who Should Apply
We’re looking for founders advancing transformative solutions in therapeutics, biotechnology, or drug delivery with the following in place:
- A defined scientific innovation with early validation
- Completed foundational market research
- A business model and milestone roadmap
- At least $50,000 raised (dilutive or non-dilutive)
- A plan to fundraise within the next 12 months
Preference will be given to companies based in or expanding to the Mid-Atlantic region.
What Founders Are Saying
“Science Inc. was a great platform to build our network beyond our local ecosystem. The advisors had real, meaningful experience in building life science businesses from the ground up.”
— Spencer Matonis, CEO, Edulis Therapeutics